Therabron Therapeutics Inc., of Rockville, Md., said the FDA granted rare pediatric disease designation to rhCC10 (recombinant human club cell 10 kDa protein), the company's lead product candidate, for the prevention of bronchopulmonary dysplasia and chronic respiratory morbidity (CRM) in preterm infants.